



(51) International Patent Classification:

C07D 519/00 (2006.01) *A61P 9/10* (2006.01)
A61K 31/517 (2006.01)

(21) International Application Number:

PCT/IB2012/057726

(22) International Filing Date:

26 December 2012 (26.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1162486 28 December 2011 (28.12.2011) FR

(71) Applicant: SANOFI [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) Inventors: **BENAZET, Alexandre**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **GUILLO, Nathalie**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR).(74) Agent: **CATILLON, Marie**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF



(M)

(57) Abstract: The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce FGFR dimerization, having the general formula: M₁-L-M₂ in which M₁ and M₂, which may be identical or different, each represent, independently of one another, a monomer unit and L represents a linker group which links M₁ and M₂ covalently with the monomer unit which follows (Formula M). Process for the preparation thereof and therapeutic use thereof.